Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
The Kerluxe brand philosophy is to employ innovation synonymous with Swiss skincar...
The Kerluxe brand philosophy is to employ innov...
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, incl...
Harrow Health, Inc. (NASDAQ: HROW) owns a portf...
ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...
ILLUSIO is a plastic surgery simulation tool th...
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...
Founded in November 2012, ObsEva is a clinical-...
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the disc...
vTv Therapeutics is a clinical-stage biopharmac...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...
Join the National Investor Network and get the latest information with your interests in mind.